AB-1002 clinical trials

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

This study is testing a new treatment, AB-1002, for a type of heart failure called non-ischemic heart failure. It aims to see if it's safe and helps improve symptoms in people whose heart failure is classed as NYHA Class III. Patients will be randomly assigned to receive the treatment or a placebo.